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ABSTRACT
Objectives: To determine whether immunotherapy of chronic HIV-1 infection can prevent or
attenuate viremia upon antiviral discontinuation.
Design: This was a Phase II randomized, partially double blinded, 232 factorial study of three
steps of 12 wk/step. Step I involved four groups: (1) vaccine placebo, (2) vaccine (ALVAC,
vCP1452), (3) placebo þ interleukin 2 (IL-2), and (4) vaccine þ IL-2. Step II involved a 12-wk
diagnostic treatment interruption (DTI). Step III involved an extension of the DTI for an
additional 12 wk.
Setting: The Weill-Cornell General Clinical Research Center.
Participants: Chronically infected HIV-1 positive adults with undetectable HIV-1 levels and .
400 CD4
þ T cells/ll.
Interventions An HIV canarypox vaccine (vCP1452) and vaccine placebo, administered every
4 wk for four doses, and low-dose IL-2 administered daily for 12–24 wk.
Outcome measures: Primary endpoints: (1) Proportion of participants with undetectable
plasma HIV RNA during trial Step II, (2) mean log10 HIV RNA copies/ml ([HIV]) from weeks 21–25,
and (3) proportion of individuals eligible for trial Step III.
Results: 44 participants were randomized, but 16 withdrew or were withdrawn before
completing Step II. As all participants underwent viral relapse in Step II, the study was
terminated after 28 participants completed Step II. Among the four groups, there was no
difference in mean [HIV] or the proportion of individuals with , log10 4.48 HIV; no difference
between the mean [HIV] of the two groups that received ALVAC (n ¼ 17) versus placebo (n ¼
11); and no significant difference between the mean [HIV] of the two groups that received IL-2
(n ¼ 11) versus placebo (n ¼ 17).
Conclusions: Neither ALVAC (vCP1452) nor low-dose daily IL-2 nor their combination
prevented the relapse of viremia upon discontinuation of antiviral therapy.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PLoS CLINICAL TRIALSINTRODUCTION
Highly active antiretroviral therapy (HAART) is effective in
suppressing viral replication in HIV infection, but the
infection cannot be eradicated, as evidenced by a rapid
return of viremia upon discontinuation of antiretrovirals [1–
3]. Therefore, the paramount question now before the HIV
community is whether it is actually possible to cure this
infection, and if so how [4]? Some suggest that the immune
system has already suffered irreparable damage by the time
the infection is ﬁrst diagnosed, thereby precluding complete
elimination of the virus. This notion served as the rationale
for treating with HAART as soon as possible after infection
[5,6]. Unfortunately, by the time the infection is recognized,
usually by the onset of systemic constitutional symptoms,
several weeks have elapsed and the infection is already
widespread. Thus, even the early institution of HAART has
failed to effect a cure [7].
Fortunately, there are some infected individuals, albeit
r a r e ,w h oa r ea b l et oc o n t a i nt h ev i r u sa n dm a i n t a i n
undetectable plasma HIV concentrations for years without
any detectable deterioration of immune function [8,9]. These
individuals, termed long-term nonprogressors (LTNPs), have
come under intense study by immunologists, who have
compared the characteristics of the immune systems of
LTNPs with the systems of individuals termed ‘‘progressors,’’
who have persistent plasma HIV concentrations and slowly
progressive deterioration of immune function. Of all of the
immunological tests performed on LTNPs versus progressors,
the consistent ﬁndings among progressors has been a
diminution of circulating CD4
þ T cells, as well as a deﬁciency
of interleukin 2 (IL-2) production by T cells in response to
stimulation by HIV antigens in vitro [10–13]. One conse-
quence of the inability to produce IL-2, which is the
predominant T cell growth factor for mature peripheral T
cells [14], is a deﬁcient T cell proliferative capacity, and early
in the epidemic this was one of the ﬁrst defects demonstrable
in vitro in T cells from HIV-infected individuals [15,16].
In lightof these considerations, weperformed a preliminary
clinical trial to test the capacity of low-dose daily IL-2
administration to boost the immune function of individuals
chronically infected with HIV, the results of which were
reported in 2000 [17]. Eligible individuals had responded to
HAART and had undetectable plasma HIV concentrations
(below 50 HIV RNA copies/ml, or [HIV]), as well as CD4
þT cell
concentrationsabove400 cells/ll.To testtheability of thehost
immune defenses to control viral replication, we continued
daily low-dose IL-2 administration, but interrupted HAART
for a minimum of eight weeks (termed a ‘‘diagnostic treatment
interruption’’ [DTI]), eventually in a total of 15 participants.
The phrase ‘‘analytical treatment interruption’’ has also been
used to distinguish this approach from a ‘‘structured treat-
ment interruption,’’ which was used as a therapeutic attempt
to allow a short-term viral relapse to serve as an endogenous
immunization with the individual’s own virus.
We found that all participants became viremic rapidly and
underwent a peak viremia, with a subsequent 10-fold decline
in plasma virus to a trough. Coincident with the reappearance
of viremia, but lagging behind the peak plasma virus
concentration by about two weeks, was a doubling in the
concentration of CD8
þ T cells. As well, the mean circulating
CD8
þ T cell concentration remained elevated as the peak
plasma HIV concentration declined to the lower, more stable
trough concentration. By comparison, the circulating CD4
þT
cell concentration transiently decreased only about 25%, soon
after the peak in viremia, while the circulating natural killer
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Editorial Commentary
Background: Currently, providing that an individual infected with HIV
can get access to highly active antiretroviral therapy (HAART), prognosis
can be very good. However, although these treatments suppress
replication of HIV, they do not eliminate HIV entirely. One current area of
HIV research focuses on whether and how it is possible to take a break
from antiretroviral therapy—which is very toxic—and at the same time
achieve very low levels of HIV. Some research groups are also interested
in whetherandhowitmightbe possibletoeliminatetheviruscompletely
from the bloodstream and immune system of infected people, and
therefore achieve a long-term cure. One such approach involves
administration of interleukin-2 (IL-2, a hormone involved in the immune
response), in the hope that IL-2 will boost the ability of the body’s own
immune system to eliminate HIV. Various candidate HIV vaccines have
also been designed that, it is hoped, will prime the immune system to
make it more receptive to IL-2. In the trial reported here, the researchers
wantedto test whether IL-2 administrationeither alone or in combination
with an HIV vaccine, ALVAC vCP1452, would maintain low levels of HIV in
the blood of people who had stopped taking antiretroviral drugs.
Therefore, participants in the trial were assigned to one of four arms: a
placebo version of the vaccine only; vaccine only; placebo version of
vaccine plus IL-2; or vaccine plus IL-2. The investigators planned to recruit
92 people into the trial who would be given the various interventions
tested here for 12 weeks, while also receiving HAART (step 1). Then,
HAART was stopped for 12 weeks (step 2), or, in some people, for 24
weeks if HIV levels remained below a certain threshold (step 3).
What the trial shows: 44 people were recruited into the study, but it was
terminated once results were analysed from those individuals who had
completed 12 weeks without HAART. The researchers did not see any
significant differences between the treatment groups in any of the three
primary outcome measures, which were the proportion of people with
undetectable HIV levels during step 2; the average HIV levels during the
last four weeks of step 2; and the proportion of people eligible to
continue to step 3. Therefore, the investigators concluded that neither
the ALVAC vaccine nor IL-2 alone or in combination with each other,
prevented HIV from replicating when HAART was stopped.
Strengths and limitations: In the trial, randomized assignment to the
different treatments was performed by the dispensing pharmacist, so
study investigators were not able to predict which treatments the next
participant would receive. A further strength in the design of this trial is
the use of a placebo vaccine to control for ALVAC vCP1452, which
enabled participants and investigators to be blinded to whether a patient
received vaccine or placebo. However, a placebo was not used as a
control for IL-2 because patients often experience characteristic side
effects to this treatment. Limitations in the design of this study include
the small numbers of participants, which meansthat the trial did nothave
enoughpowertoexcludethe possibilityof asmall effectof IL-2 or vaccine
on HIV levels in blood. The follow-up in the trial was also short, and
efficacy outcomes did not include measures that patients might consider
important, such as survival.
Contribution to the evidence: Currently, large-scale trials are evaluating
the clinical effectiveness and safety of IL-2 at higher doses than those
tested here, together with antiretroviral drugs as treatment for HIV. This
study adds data suggesting that IL-2 at a lower dose either with or
without the ALVAC vCP1452 vaccine does not prevent HIV replication
once antiretroviral drug treatment is stopped.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.cell concentration remained elevated due to the IL-2 admin-
istration, and unchanged throughout the eight-week DTI.
Based on these results [16], it appeared that the DTI
approach could be used to design a new trial to test
immunotherapeutics to boost immune reactivity to HIV.
Because low-dose daily IL-2 administration in and of itself
had not prevented the viral relapse, we reasoned that a more
rational approach to immunotherapy would be to introduce a
candidate HIV vaccine to activate the T cell expression of IL-
2 receptors, so as to render these cells responsive to the
growth-promoting, differentiative, and survival effects of IL-2
before the DTI [14,18,19].
Of the candidate HIV vaccines available for testing,
ALVAC, a vaccine produced by Sanoﬁ Pasteur using the
canarypox virus as vector, had received the most extensive
safety and efﬁcacy testing in ﬁeld trials in HIV-negative,
healthy volunteers [20–23]. No severe reactions (grade III or
grade IV) had been observed that were attributable to the
vaccine. Thus, the second-generation vaccine, vCP1452,
which contains the clade B HIV-1 env and gag genes and a
synthetic polypeptide encompassing the known human CTL
epitopes from the nef and pol gene products, was chosen for
testing for the ﬁrst time in HIV-positive individuals. This
vector also contains two vaccinia virus-derived genes, E3L
and K3L, which enhance the overall efﬁciency of antigen
expression.
This report details the interim results from our trial, in
which we tested vCP1452 with and without the daily
administration of IL-2 as a vaccine adjuvant in a factorial
design, and with a DTI as the basis for the clinical trial end
point. The rationale followed from our preliminary study
[17], which indicated that promotion of a T cell HIV-speciﬁc
immune response may prevent or attenuate a viral relapse
upon discontinuation of antivirals.
METHODS
Participants
Individuals eligible for study were chronically infected (i.e., .
6 mo) adults (aged   18 y) with a positive HIV serology who
had never had a CD4
þ T cell concentration below 200 cells/ll,
and who were on HAART (deﬁned as a combination of at
least three effective antiretroviral agents), with undetectable
plasma HIV concentrations (, 50 copies/ml) and circulating
CD4
þ T cell concentrations 400 cells/ll or above on two
occasions 14 d apart within 30 d of enrollment. Individuals
were excluded if there was a history of hypersensitivity to any
of the study agents, or to eggs and/or birds, especially
canaries. Prior exposure to IL-2 must have terminated at
least 30 d prior to study entry. Additional exclusion criteria
included any prior receipt of an HIV vaccine, a current AIDS-
deﬁning illness, documentation of virologic failure (i.e.,
.10,000 [HIV]) while receiving the current HAART regimen,
or a history of thyroid disease, or autoimmune disorders,
including asthma, inﬂammatory bowel disease, rheumatoid
arthritis, or psoriasis. Participants were recruited via radio,
TV, and print advertisements, as well as via referrals from
their primary care physicians. All participants signed a
written informed consent form approved by the Weill
Medical College of Cornell University Institutional Review
Board, which also reviewed the consent form and protocol to
ensure that the investigation was conducted according to the
principles expressed in the Declaration of Helsinki.
Objectives
This study was designed to test the hypothesis that immuno-
logical enhancement during maximal viral suppression by
antiviral drugs can boost the host defenses reactive with the
virus, so that upon cessation of antiviral therapy, the plasma
virus concentration would remain below detectable levels.
Alternatively, should viremia recur, it was hypothesized that
immunotherapy would maintain the plasma virus concen-
tration at lower levels than in the absence of immunological
enhancement. A secondary objective was to test the hypoth-
esis that the concentrations of circulating HIV p55 gag-
speciﬁc T cells would correlate with control of plasma virus
concentrations.
Interventions
This was a phase II, randomized, controlled, partially double-
blinded, single center, 232 factorial three-step study to test
whether immune-based therapies consisting of an HIV
canarypox vaccine and/or daily low dose IL-2 administration
provided augmented host antiviral activity, as tested by
monitoring plasma HIV concentrations upon cessation of
HAART.
Participants were randomized, doubly blinded as to vaccine
versus placebo, to one of four groups in Step I as follows: (1)
vaccine placebo; (2) vaccine; (3) vaccine placebo þ IL-2; and
(4) vaccine þ IL-2.
During Step I, all participants continued to receive
HAART, and in addition received four intramuscular
inoculations of vCP1452 vaccine (10
6.5 TCID50) or placebo
(vaccine excipient, 0.5 ml) at weeks 0, 4, 8, and 12. The study
investigators inoculated vaccine and/or placebo into alter-
nating deltoid muscles.
Those participants randomized to receive IL-2, self-
administered daily subcutaneous low-dose (1.2 million U [80
lg]/M
2 BSA) IL-2 as Proleukin (Chiron Corporation, http://
www.chiron.com) injections at sites (abdomen, thighs) distinct
from the intramuscular vaccine and/or placebo inoculations
throughout the entire study interval of 37 wk, taking care not
to inject into the same area on consecutive days because of
the known local injection-site delayed-type hypersensitivity
reaction elicited by IL-2 [24,25]. Because of this reaction at
the site of IL-2 injection, it was considered impossible to
blind the IL-2 administration, so it was given open label.
To ensure accuracy of the IL-2 dose administered, the
investigational pharmacist at The New York Presbyterian
Hospital prepared syringes, each containing a daily dose for
14 d. Each Proleukin vial containing 1.2 mg and 22 million U
of IL-2 activity (speciﬁc activity ¼ 18.3 million U/mg) was
reconstituted with 1.2 ml of sterile water, then diluted further
with 4.8 ml of 5% dextrose in water to a ﬁnal volume of 6.0 ml
(speciﬁc activity ¼ 3.67 million U [200 lg]/ml). Thus, for an
average adult of 1.7 M
2 BSA, the daily dose was 2 million U
(136 lg) in a volume of 0.54 ml. Had the contents of the vial
not been diluted, the volume necessary to inject only 2
million U (136 ll) would have been too small to measure
accurately in a 1 ml syringe.
At the end of Step I, participants who met eligibility criteria
entered Step II, i.e. the DTI, when HAART was discontinued
for a minimum of 12 wk. During Step II, as a safety precaution
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circulating CD4
þT cell concentration fell below 250 cells/llo r
50% orless of the mean baseline CD4
þT cell concentration on
two successive determinations. At the end of Step II,
participants were declared off-protocol if the mean plasma
[HIV] was 30,000 copies/ml or over during the last 5 wk of
study (i.e., weeks 21–25). If the mean plasma [HIV] remained
below this threshold, the participants were permitted to
remain on study and entered Step III, which consisted of a
continuation of the DTI for another 12 wk. During this
interval, if the HIV or CD4
þ T cell thresholds were surpassed
on two successive determinations, the participant was
declared off protocol. At the end of the Step III (week 37),
all participants were declared off-protocol and IL-2 admin-
istration was discontinued. When a participant completed the
protocol at either the end of Step II or Step III, decisions
regarding future HIV medications reverted to the participant,
in consultation with the appropriate health care provider.
Concomitant Medications
During Step I, adjustments or changes in antiretroviral drugs
were permitted if for reasons other than virologic failure,
such as for ease of administration or because of side effects.
Topical corticosteroid use was acceptable, provided it was
applied to a site separate from IL-2 and vaccine injection
sites. Maintenance therapy for opportunistic infections that
developed on study treatment was permitted according to
standard medical care, except for foscarnet during IL-2
administration, and rifabutin and rifampin at any time.
Other permitted medications were maintenance therapy for
recurrent genital herpes with 1,000 mg/day or less of
acyclovir, erythropoietin and G-CSF, all antibiotics for
bacterial infections as clinically indicated, medications for
symptomatic treatment such as antipyretics and analgesics
(ibuprofen and acetaminophen were the preferred agents),
and concomitant use of thyroid hormone replacement to
manage hypothyroidism.
The following drugs were excluded during study: interfer-
ons, other interleukins, other HIV vaccines, sargramostim
(GM-CSF), dinitrochlorobenzene (DNCB), thymosin alpha 1
(thymosin alpha), thymopentin, inosiplex (Isoprinosine),
polyribonucleoside (Ampligen), ditiocarb sodium (Imuthiol),
investigational antiretroviral agents, thalidomide, St. John’s
wort, systemic or local cytotoxic chemotherapy for malig-
nancy, and systemic corticosteroids.
Schedule of Evaluations
During Step I, clinical and laboratory evaluations were
performed prior to each vaccine or placebo inoculation at
4-wk intervals. During Step II, clinical and laboratory
evaluations were performed weekly, and during Step III,
clinical and laboratory evaluations were obtained bimonthly.
All clinical observations were recorded in a secure electronic
database. Laboratory data were transferred electronically
daily from the New York Presbyterian Hospital Laboratory
computer to the electronic database.
Laboratory Evaluations
Lymphocyte subset concentrations were monitored by the
New York Presbyterian Hospital Laboratory using standard
methods for performing ﬂow cytometry. HIV-speciﬁc cyto-
kine-producing lymphocyte precursor (CPLp) concentrations
were determined after a short-term in vitro activation with a
15-mer peptide pool overlapping every 11 amino acids
predicted by the entire coding region of the HIV p55 gag
gene sequence. See Text S1 for details.
Outcomes
Antiretroviral therapy was interrupted for a minimum of 12
wk during Step II, and three primary endpoints were used for
evaluating immune control of viral replication, based upon
plasma [HIV] (see Text S1); (1) the proportion of participants
who had undetectable plasma [HIV] during Step II, (2) the
mean of the log10 [HIV] obtained from weekly blood samples
during on-study weeks 21–25, which corresponded to weeks
8–12 following the cessation of HAART, and (3) the
proportion of participants who were eligible to progress to
Step III, as determined by mean plasma [HIV] of (, 30,000
[log10 4.48] copies/ml during the last ﬁve weeks of Step II (i.e.,
weeks 21–25). This criterion was based on our preliminary
data from an addition of six participants to the nine reported
originally [16] who received daily low dose IL-2 during an 8-
wk DTI. The data from this group of 15 participants revealed
that there were 8/15 volunteers who had a mean trough
plasma [HIV] below 30,000 (log10 ¼ 4.48). This group had a
mean 6 standard deviation of 3.77 6 0.27 copies/ml, whereas
7/15 volunteers who had a mean trough plasma [HIV] .
30,000 (log10¼4.48), had a mean of 4.82 6 0.31 copies/ml. The
difference between the means of the two groups was
signiﬁcant (p , 10
 4, two-tailed Student’s t-test).
Sample Size
It was calculated that 23 participants/group would be
required, assuming a dropout rate of 25%, resulting in 17
evaluable patients per arm. Based on our previous open label
study using daily low-dose subcutaneous IL-2 administration
both before and after the cessation of HAART, the mean
plateau value 6 standard deviation of the ‘‘trough’’ plasma
[HIV] of nine participants was 4.2 6 0.5 log10. Using a
Bonferroni-adjusted t-test approach to the power calculation
for comparing each of the three active treatment arms to the
vaccine placebo control group (alpha ¼ 0.05/3 ¼ 0.017), this
yielded 90% power for detecting a difference of 0.65 log units
of the mean plasma [HIV].
Randomization
The investigational pharmacist assigned participants to
receive IL-2 or not, and to receive ALVAC or not, according
to a computer-generated randomization procedure. A bal-
anced selection process consisted of 11 blocks of four
participants each, and resulted in the assignment of 11
participants to each of the four treatment groups. The
random allocation sequence was concealed from the study
investigators and participants via a telephone call to the
pharmacist. After assignment to a treatment group by the
pharmacist, the study investigators were informed as to
whether the participant would receive IL-2 or not. The
pharmacist then furnished syringes containing the ﬁrst 14-d
supply of IL-2, along with a syringe containing vaccine or
placebo for administration by the study investigator.
Blinding
Participants, study investigators, and laboratory personnel
were all blinded to vaccine or placebo group assignment.
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was not possible for either the study investigators or the
participants to discern whether vaccine or placebo was
administered. The IL-2, in contrast, was administered in
open-label fashion because it caused a local inﬂammatory
reaction at the site of administration.
Statistical Methods
Mean log10 plasma [HIV] values were compared using
ANOVA for a 232 factorial design. Initially, the vaccine 3
IL-2 interaction term was evaluated in order to determine
whether the difference in viral load response between vaccine
and placebo control varied according to whether or not IL-2
was administered. If the interaction was signiﬁcant, then
speciﬁc ‘‘within level’’ contrasts were performed. A Fisher
exact test was used to compare proportions between the four
experimental groups.
A second set of statistical analyses focused on the behavior
of circulating CD4
þand CD8
þcell concentrations during Step
II (weeks 13–25) as compared to the mean of three baseline
determinations (100%). Repeated measures analysis of
variance, or RMANOVA, using the mixed model approach
(SAS PROC MIXED) was applied to each of these parameters
to determine the effects of time, IL-2, and vaccine. Terms for
the interaction between IL-2 and vaccine, as well as for time
were included. In addition, the mean plasma log10 [HIV] from
the last 5 wk of Step II (weeks 21–25) were computed and
compared with the mean circulating CD4
þ and CD8
þ T cell
concentrations for each person individually and then for the
group eligible for Step III and the group ineligible for Step
III. Then the Pearson correlation coefﬁcients between the
mean plasma log10 [HIV] and mean CD4
þ and CD8
þ T cell
concentrations were computed.
A repeated measures ANOVA using the mixed model was
used to examine changes in circulating HIV gag p55-speciﬁc
CPLp concentrations over three time intervals in the study
(i.e., background [week 0], at the end of Step I [week 13], and
during the viremic phase of Step II [week 21]), and across
treatment groups (i.e., A, B, C, and D). A group 3 time
interaction term was included in the model and a compound
symmetry covariance structure was assumed. A result was
considered statistically signiﬁcant if p , 0.05.
Interim Analysis
An interim analysis was planned for efﬁcacy, after half of the
projected sample size was followed for the required 25 wk.
Thus, the interim analysis was planned when 34 participants
completed Step II (calculated based upon a dropout rate of
25%, yielding 92 enrolled participants375%/2¼34). At that
time, the 232 factorial ANOVA was to be used. Using a Lan-
DeMets version of an O’Brien-Fleming group sequential
stopping rule, the trial was to be stopped if at least one of the
three tests (i.e., main effect for vaccine, main effect for IL-2,
or interaction) was statistically signiﬁcant at the alpha ¼
0.00305 signiﬁcance level. If none of the tests was signiﬁcant,
then the trial was to continue until the planned termination
with 92 individuals enrolled and 68 had completed Step II.
The ﬁnal ANOVA was planned to be carried out at the alpha
¼ 0.04695 signiﬁcance level, to preserve the projected
statistical powers.
RESULTS
Participant Flow
Between December 2000 and February 2005, 110 individuals
were screened for eligibility. Of these, 66 (60% of total) were
excluded: 43 (65%) were ineligible, 21 (32%) were not
interested, and two (3%) did not meet the study entry criteria
according to the opinion of the investigators. Of the 44
participants enrolled (40% of total), 11 were randomly
assigned to each experimental group (Figure 1). In group A,
three participants were terminated according to protocol
during Step II because of low CD4
þ T cell concentrations. Of
the eight participants who completed Step II, ﬁve were
ineligible to continue to Step III because of plasma [HIV] in
excess 30,000 copies/ml. One participant who was eligible for
Step III withdrew from the study rather than continue the
DTI. In group B, one participant withdrew consent before
receiving study medications, and one participant withdrew
consent during Step I because he/she wanted to discontinue
HAART immediately and not wait for Step II. Of the nine
participants who ﬁnished Step II, seven were eligible for Step
III, whereas two participants were not eligible due to plasma
[HIV] over 30,000 copies/ml. In group C, four participants
withdrew during Step I because of intolerance to IL-2
injections, one withdrew during Step II because he/she
wanted to restart HAART, two were terminated because of
the development of hyperthyroidism, and one was terminated
because of low CD4
þ T cell concentrations. Of the three
participants who ﬁnished Step II, only one was eligible for
Step III. In group D, two participants withdrew during Step I
because of intolerance to the IL-2 injections, and one was
terminated because of the development of antibodies reactive
with Proleukin. Of the eight participants who completed Step
II, only three were eligible for Step III.
Of the 44 participants enrolled to the study over 44
months, 28 (65%) completed Step II and were evaluable at the
time of the interim analysis. Of these 28 participants, 14
qualiﬁed for Step III, and only one of 14 elected not to
continue to enter Step III.
In view of a viral relapse in all participants during Step II,
Figure 1. Participant Flow
Each box represents the flow of participants through the study, from
screening to enrollment to randomization and analysis. AE, adverse event
necessitating withdrawal from study; WD, individual withdrew from study
(see text).
doi:10.1371/journal.pctr.0020005.g001
www.plosclinicaltrials.org January | 2007 | e5 0005
Immunotherapy for HIV Infectionwhich was the ﬁrst primary endpoint, as well as the slow rate
of enrollment of about one participant per month, and the
higher than expected termination rate (i.e., 36% observed
versus 25% expected), with agreement by the study sponsors
it was elected to perform an interim analysis after 28 rather
than 34 participants had completed Step II and were
therefore evaluable.
Baseline Data
Between May 2001 and November 2004, 44 participants were
enrolled. Enrolled participants attended two screening visits
and three baseline visits from which baseline data were
obtained. There were three females and 41 males. The
average age of volunteers was 41 y (range 22–63 y). The mean
ages of participants randomized to the four treatment groups
were similar (Table 1). Also listed are the mean lymphocyte
subset concentrations. Within the total participant popula-
tion, the mean 6 standard error of the mean (SEM) CD4
þ T
cell concentration was 648 6 28 cells/ll, while the mean CD8
þ
T cell concentration was 891 6 56 cells/ll. As shown in Table
1, there was not a signiﬁcant difference of the T cell subset
concentrations among the four treatment groups.
Outcomes and Estimation: Primary Outcomes
Viral dynamics. The plasma [HIV] of all participants
remained undetectable throughout Step I. Figure 2 shows
the viral dynamics for each participant according to study
group during Step II and Step III. It is evident from these
plots, that all individuals relapsed in Step II after the
discontinuation of HAART (the ﬁrst primary endpoint), and
the onset of detectable viremia was variable, ranging from 1
to 7 wk. The peak plasma [HIV] ranged from 3 to 6 log10, and
the plasma [HIV] of each participant reached the plateau
phase during the last 5 wk of Step II (study weeks 21–25), i.e.,
8–12 weeks after the antiviral treatment interruption (the
second primary endpoint). Thereafter, those participants
eligible to proceed to Step III (the third primary endpoint)
maintained stable plasma [HIV] throughout the additional
12-wk Step III interval (i.e., study weeks 25–37).
Analysis of the mean plasma [HIV] in log10 copies/ml of the
four groups during the last 5 wk of Step II (the second
primary endpoint) were not signiﬁcantly different when
compared with one another (Figure 3). Based on a 232
ANOVA there was no effect of vaccine (p¼0.62), nor IL-2 (p¼
0.94), nor a synergistic or antagonistic effect between the
vaccine and IL-2 as evidenced by the lack of a signiﬁcant
interaction (p ¼ 0.68). As well, the percentage of participants
with plasma [HIV] below 30,000 (, log10 4.48) copies/ml
varied from 33% to 78% among the separate treatment
groups (the third primary endpoint), but again these differ-
ences were not signiﬁcant based on a Fischer exact test. In
this regard, it is important to emphasize that the number of
participants in each experimental group would not have been
predicted to approach signiﬁcance, based upon our study
design.
However, based on these results, and in view of the
differential termination rate among the four groups, it was
elected to unblind and terminate the study. Accordingly, it
was determined that group A received the vaccine placebo; B,
vaccine; C, placebo þ IL-2; and D, vaccine þ IL-2 (Figure 3).
Because of the differential termination rate with more
participants terminated from groups C and D than from
groups A and B, group C (placebo þ IL-2) had only three
participants evaluable.
Outcomes and Estimation: Secondary Outcomes
Lymphocyte dynamics. In the context of CD8
þ T cell
concentrations from each experimental therapy group
during Step II, there was a signiﬁcant interaction between
IL-2 and vaccine. In the absence of IL-2 administration, the
use of vaccine (group B) did not result in a signiﬁcant
increase in circulating CD8
þ T cell concentrations compared
with placebo (group A) (p . 0.3). However, the circulating
CD8
þ T cell concentrations were increased signiﬁcantly when
IL-2 was coadministered with vaccine (group D) (p , 0.002)
(Figure 4A).
For CD4
þ T cell concentrations, statistical analysis showed
no interaction between IL-2 and vaccine, but there was a
main effect of IL-2 (p , 0.0001) and no effect of vaccine. That
is, the use of IL-2 was associated with increased concen-
trations of circulating CD4
þ T cells, and this increase was
statistically similar whether vaccine was administered or not
(Figure 4B). In addition, there was a signiﬁcant negative
correlation for the group eligible for Step III between the
mean plasma log10 [HIV] and the mean CD4
þ Tc e l l
concentration (r  0.66, p , 0.01).
Changes in HIV p55 gag-Reactive T Cell
Concentrations
The changes in circulating HIV p55 gag-speciﬁc CD8
þ T cell
concentrations among the four treatment groups as moni-
tored by interferon gamma (IFN-c)–secreting CPLps are
depicted in Figure 5A. There were no signiﬁcant differences
according to treatment group (p ¼ 0.21), but the cell
concentrations increased signiﬁcantly at Step II relative to
Step I and background (p , 0.001). As well, as shown in Figure
5B, there were no signiﬁcant differences in circulating HIV
p55 gag-speciﬁc CD4
þ T cell concentrations among the four
treatment groups (p ¼ 0.20), but the CD4
þ T cell CPLps
increased signiﬁcantly at Step II relative to Step I and
background (p , 0.01).
Similar results were obtained comparing tumor necrosis
.......................................................................................................................................................................................
Table 1. The Demographics of the Study Participants Showed Equal Distribution among All Treatment Groups
Group Characteristic All Groups Group A: Placebo Group B: Vaccine Group C: IL-2 Group D: Vaccine þ IL-2
Number 44 11 11 11 11
Male/female ratio 41/3 11/0 11/0 11/0 8/3
Mean age, y (range) 41 (22–63) 42 (26–65) 41 (31–58) 42 (27–63) 40 (22–52)
Mean CD4
þ T cells/ll (SEM) 648 (28) 607 (49) 673 (64) 656 (67) 657 (67)
Mean CD8
þ T cells/ll (SEM) 891 (56) 1,013 (147) 744 (91) 966 (104) 839 (89)
doi:10.1371/journal.pctr.0020005.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Immunotherapy for HIV Infectionfactor alpha (TNF-a)–secreting CD8
þ CPLps as shown in
Figure 6A. There were no signiﬁcant differences according to
treatment group (p ¼ 0.43), but there was a signiﬁcant
increase at Step II relative to Step I and background (p ¼
0.01). By comparison, there were no signiﬁcant differences in
CD4
þ TNF-a–secreting CPLps comparing the treatment
groups (p ¼ 0.75) or the time intervals during the study (p ¼
0.09) (Figure 6B).
Compared with the IFN-c and TNF-a CPLp concentrations,
the IL-2–secreting CPLp concentrations were an order of
magnitude lower overall (Figure 7). The CD8
þ IL-2–secreting
CPLps were not signiﬁcantly different comparing treatment
groups (p ¼ 0.53), or comparing time intervals of the study (p
¼ 0.06) (Figure 7A). The CD4
þ IL-2–secreting CPLp concen-
trations were not signiﬁcantly different comparing treatment
groups (p ¼ 0.52), but there was a signiﬁcant increase at Step
II compared with Step I or background (p , 0.03) (Figure 7B).
Adverse Events
The NIAID Division of AIDS Table for grading Severity of
Adult Adverse Experiences (http://rcc.tech-res.com/
tox_tables.htm) was used for reporting adverse events.
Toxicity was graded on a scale of I to IV, with severe and
life-threatening events graded as III or IV, respectively.
A total of 610 AEs were reported; of which 529 (86.7%)
were grade I, 77 were grade II (12.6%), and only four (0.7%)
were grade III. The grade III AEs consisted of allergy to IL-2
(one, group D), and neutropenia (three—one in group A and
two group C). There were no grade IV AEs and there were no
serious AEs (SAEs). Table 2 lists the types of AEs higher than
grade I, as the number and percent of the total AEs observed,
as well as those in each of the four experimental groups.
There were no protocol deviations.
DISCUSSION
Interpretation
The results obtained from this Phase II immunotherapy trial
for individuals with chronic HIV infection indicate that
neither four monthly intramuscular inoculations of ALVAC
(vCP1452), nor daily low dose IL-2 subcutaneous injections,
nor their combination, can prevent a viral relapse when
antiretroviral therapy is discontinued.
Because all participants relapsed when antiretrovirals were
Figure 2. Plasma [HIV] during Steps II and III of Individuals According to Immunotherapy Treatment Group
Red vertical line in center of each figure depicts the demarcation between Step II and Step III. Fractions in upper right corner of each figure portray the number of
participants who were eligible to enter Step III in each group.
doi:10.1371/journal.pctr.0020005.g002
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Immunotherapy for HIV Infectiondiscontinued, the study was terminated prematurely. This
decision was also inﬂuenced by the slow enrollment rate of
only one participant per month and a dropout/termination
rate greater than anticipated (i.e., 36% versus 25%). Accord-
ingly, additional trials will be necessary to determine whether
this immunotherapy protocol can yield beneﬁt by attenuating
rather than actually preventing the viral relapse.
The difﬁculty in enrollment was due to several problems,
including (1) it was a randomized study with a chance of one-
fourth that a volunteer would be randomized to no
experimental therapy, (2) the study involved a treatment
interruption, (3) there were frequent clinic visits, (4) the
participants who received IL-2 had to self-inject daily, and (5)
many physicians and patients were skeptical that immuno-
therapy would yield any beneﬁt.
With regard to enrolled participants who were discon-
tinued from the study, particularly noteworthy was a differ-
ential dropout/termination rate from the groups that
received IL-2. Of the 11 participants lost from the IL-2
treatment groups, six dropped out early in the study because
they were unable or unwilling to undergo daily self-injections,
or because of the mild (grade I) local inﬂammatory reaction
or the mild (grade I) systemic constitutional symptoms
associated with low-dose IL-2 administration (i.e., malaise,
myalgia, fever). Accordingly, even though the dose of IL-2 was
low enough to avoid most of the severe systemic constitu-
tional signs and symptoms of inﬂammation associated with
higher IL-2 doses, it is clear that low-dose IL-2 administration
is hampered by the fact that it must be injected daily, and still
causes both local and systemic inﬂammation.
With regard to AEs, it is worthy of mention that only 13%
of the AEs were higher than grade I, and there were no grade
IV AEs or SAEs. As well, there were no instances of a
‘‘retroviral syndrome’’ severe enough to cause withdrawal
from the study. Accordingly, this clinical trial design for
healthy HIV-positive individuals on antiretrovirals is well
tolerated. It is also noteworthy that there were few AEs
attributable to the administration of the vaccine.
Generalizability
The fact that all participants underwent a viral relapse within
a few weeks after antivirals were discontinued was disconcert-
ing in view of the hope that some individuals might mount an
immune response effective enough to control viral replica-
tion, especially because the total viral burden had been
reduced to low levels by antiviral chemotherapy. Our ﬁndings
argue strongly that additional studies are necessary to more
fully understand the failure of the immune system to control
viral replication in these patients. In this regard, it is
especially disappointing that IL-2 administration had no
discernible effect, given the numerous studies, noted pre-
viously, that point to a defect in IL-2 production as one of the
hallmarks of the immunodeﬁciency of chronic HIV infection.
The heterogeneity of individuals with regard to the viral
dynamics in Step II (Figure 3) should be taken into
consideration in the design of future immunotherapy clinical
trials. The broad range of peak and plateau plasma [HIV],
Figure 3. Results from Interim Analysis
This was a 232 factorial study with participants randomized to receive vaccine
(þ) or not ( ), and IL-2 (þ) or no-IL-2 ( ). The numbers listed in each block are
the mean plasma [HIV] log10 RNA copies/ml for each participant from the last
5 weeks of Step II (i.e., weeks 21–25). There was no significant difference
between the means of each group based on a 232 ANOVA.
doi:10.1371/journal.pctr.0020005.g003
Figure 4. Mean CD8
þ and CD4
þ T cell Concentrations of the Four
Immunotherapy Groups during Step II
(A) CD8
þ T cells.
(B) CD4
þ T cells.
Blue diamonds ¼ group A, placebo; red squares ¼ group B, vaccine; green
triangles ¼ group C, IL-2; black circles ¼ group D, IL-2 þ vaccine. Brackets
depict SEM.
doi:10.1371/journal.pctr.0020005.g004
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Immunotherapy for HIV Infectioneven in the absence of immunotherapy, is indicative of an
individual heterogeneity that will require experimental
groups of more than 17 volunteers, as estimated for this
study originally, to resolve whether differences observed
might be due to experimental therapy.
There was a deﬁnite effect of IL-2 administration, which
served to increase the concentration of circulating CD8
þ T
cells when coadministered with vaccine (Figure 4A). It is
unclear whether the magnitude of the increase can be
attributed to an effect of the vaccine, IL-2, or both from
these data, because there were only three participants
evaluable in the group that received IL-2 alone. However, it
is likely that the CD8
þ lymphocytosis was primarily due to IL-
2, in that a similar magnitude of increase was observed in our
preliminary trial that did not include vaccine [17]. IL-2 also
functioned to maintain the baseline concentrations of
circulating CD4
þ T cells after the discontinuation of the
antivirals, at least for the duration of the study. These results
Figure 5. Mean HIV p55 gag-Specific T Cells Capable of Producing IFN-c According to Treatment Group
(A) [CD8
þ T cell].
(B) [CD4
þ T cell].
Brackets depict SEM. Bkg, background.
doi:10.1371/journal.pctr.0020005.g005
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Immunotherapy for HIV Infectionsuggest that low daily doses of IL-2 might be used to maintain
the circulating CD4
þ T cell concentrations if individuals
discontinue antivirals for longer intervals. However, further
studies will be required to determine this point.
At the initiation of the study it was hoped that monitoring
the frequency of HIV p55 gag-speciﬁc T cells by ﬂow
cytometry would provide an additional parameter to com-
pare with the plateau plasma [HIV]. However, there was no
change from baseline after the immunotherapy interval (Step
I) in the concentrations of circulating HIV-speciﬁc T cells
whether monitored by IFN-c, TNF-a, or IL-2 production.
Moreover, even though there was a readily detectable
increase in circulating HIV p55 gag-speciﬁc CD4
þ and CD8
þ
T cells when monitored after the peak of viremia at week 21
during Step II, there was not a signiﬁcant difference when
comparing the treatment groups. However, these results must
be interpreted in light of a lack of difference in the viral
endpoints when comparing treatment groups. In addition,
Figure 6. Mean HIV p55 gag-Specific T Cells Capable of Producing TNF-a According to Treatment Group
(A) [CD8
þ T cell].
(B) [CD4
þ T cell].
Brackets depict SEM. Bkg, background.
doi:10.1371/journal.pctr.0020005.g006
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Immunotherapy for HIV Infectionthe increase in detectable CPLp that occurred during the
viremic phase of Step II indicates that the participants were
capable of mobilizing increased concentrations of HIV-
speciﬁc T cells, given an increased antigenic stimulus.
Accordingly, additional studies are warranted to determine
whether the CPLp assay or additional in vitro immunological
correlates of a favorable in vivo antiviral immune response
can be identiﬁed. As well, these data indicate that the
monitoring of immunological responses should be combined
with a plasma [HIV] endpoint to adequately predict any
correlation between the in vitro immunological assays and an
antiviral immune response. Also, it is possible that a stronger
Figure 7. Mean HIV p55 gag-Specific T Cells Capable of Producing IL-2 According to Treatment Group
(A) [CD8
þ T cell].
(B) [CD4
þ T cell].
Brackets depict SEM. Bkg, background.
doi:10.1371/journal.pctr.0020005.g007
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immune response, if elicited during Step I before the
discontinuation of antivirals, could serve to prevent the viral
relapse.
Perhaps the most consistent ﬁnding with regard to the
frequencies of cytokine-producing cells was the very low level
of detectable IL-2-producing cells regardless of treatment
group and throughout the study intervals that were moni-
tored. Moreover, it is noteworthy that IL-2 therapy had no
effect on IL-2–producing capacity, a result not entirely
unexpected, given the lack of inﬂuence of IL-2 on its own
gene expression [26,27]. Consequently, future studies are
necessary to focus on the IL-2 gene and its regulation to gain
additional insight into this immune defect in HIV infection.
Overall Evidence
The results of this study are consistent with those of two other
studies reported recently where the effects of either ALVAC
or IL-2, or both, were examined. The ANRS 093 study is
perhaps the most favorable study in terms of support for the
concept that immunotherapy or therapeutic immunization
before antiviral drug cessation may contribute to the capacity
of the host to contain HIV replication [28]. The AIDS Clinical
Trials Group has completed a trial (#5024), which compared
ALVAC (vCP1452) to cycles of high-dose IL-2, versus their
combination in chronically infected participants [29]. The
investigators concluded that while there was a suggestion that
therapeutic immunization might have the potential to
enhance host immune control after antiretroviral cessation,
the effect is modest (median difference ; 0.4 log10 HIV RNA
copies/ml). Moreover, even high-dose IL-2 did not appear to
add beneﬁt to the vaccine.
One must conclude from the results of these studies that
the canarypox vaccine, which cannot replicate in mammalian
cells, is a relatively weak immunogen. As already pointed out
[30], viral vectors that are replication incompetent suffer
from the inability to maximally activate antibody formation
because mature virions are not produced to stimulate B cell
recognition of native envelope structures, nor are opsonized
virions available for uptake by antigen-presenting cells for
processing and presentation of vaccine epitopes to CD4
þ T
helper cells via class II major histocompatibility complex.
Accordingly, replication-incompetent vectors must rely al-
most entirely on stimulating primarily a CTL response.
Unfortunately, almost all of the HIV vaccines currently
under development are in replication-incompetent vectors.
The one exception is being conducted in a program at the
National Cancer Institute, which is developing replication-
competent adenovirus as an HIV vaccine vector [31–33].
Their recent results, showing a durable protective CD8
þT cell
immune response to viral challenges a year apart, provide
hope that effective vaccines against HIV will eventually be
possible [33].
SUPPORTING INFORMATION
CONSORT Checklist
Found at doi:10.1371/journal.pctr.0020005.sd001 (54 KB DOC).
Trial Protocol
Found at doi:10.1371/journal.pctr.0020005.sd002 (901 KB PDF).
Text S1. Laboratory Evaluations
Found at doi:10.1371/journal.pctr.0020005.sd003 (27 KB DOC).
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Table 2. Adverse Events above Grade I
Adverse Event All Groups
(n ¼ 81)
Group A: Placebo
(n ¼ 26)
Group B: Vaccine
(n ¼ 13)
Group C: IL-2
(n ¼ 26)
Group D: Vaccine þ IL-2
(n ¼ 16)
Neutropenia 32 (39.5) 10 (38) 11 (85) 8 (31) 3 (18.8)
Lymphopenia 6 (7.4) 2 (7.7) 1 (7.7) 1 (3.8) 2 (12.5)
Depression 3 (3.7) 0 0 2 (7.7) 1 (6.3)
Fever 8 (9.9) 0 0 7 (27) 1 (6.3)
Rhinitis 8 (9.9) 5 (19.2) 0 2 (7.7) 1 (6.3)
Abnormal ALT/AST 2 (2.5) 1 (3.8) 1 (7.7) 0 0
Headache 3 (3.7) 2 (7.7) 0 0 1 (6.3)
Diarrhea 2 (2.5) 2 (7.7) 0 0 0
Night sweats 2 (2.5) 0 0 2 (7.7) 0
Fatigue 3 (3.7) 0 0 3 (11.5) 0
Thrush (oral) 1 (1.2) 0 0 0 1 (6.3)
Myalgia 1 (1.2) 0 0 0 1 (6.3)
IL-2 allergy 1 (1.2) 0 0 0 1 (6.3)
Dizziness 1 (1.2) 0 0 0 1 (6.3)
Varicella zoster outbreak 1 (1.2) 0 0 0 1 (6.3)
Rash 1 (1.2) 0 0 0 1 (6.3)
Syncope 1 (1.2) 1 (3.8) 0 0 0
Abdominal pain 1 (1.2) 1 (3.8) 0 0 0
Sore throat 1 (1.2) 1 (3.8) 0 0 0
Vomiting 1 (1.2) 1 (3.8) 0 0 0
Nausea 1 (1.2) 0 0 1 (3.8) 0
Cough 1 (1.2) 0 0 0 1 (6.3)
Number of AEs indicated by n. All data are given as number (%). No Grade IV AEs and no SAEs occurred.
doi:10.1371/journal.pctr.0020005.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
www.plosclinicaltrials.org January | 2007 | e5 0012
Immunotherapy for HIV InfectionPasteur—especially Raphaelle El Habib—for supplying the ALVAC
vaccine, the Chiron Corporation for supplying Proleukin, and all of
the study participants who made this research possible.
Author Contributions
KAS, ML, SB, CW, and JR designed the study. KAS, SA, ZP, AS, ML,
and CW analyzed the data. KAS, LKR, AS, and PB enrolled patients.
SA, ZP, LKR, SB, and CW wrote the paper. SA monitored the immune
responses of clinical trial participants. ZP was involved in laboratory
evaluations. LKR conducted protocol-speciﬁed visits to collect
clinical data from study participants and manage adverse events. SB
acted as the research pharmacist for this trial, which involved
designing the randomization scheme, randomizing patients to treat-
ment, calculating and preparing treatment doses, and blinding the
vaccine doses. CW designed experiments and analyzed data associ-
ated with the use of the CPLp assay.
Funding
This work was supported in part via a grant from the National
Institute of Allergy and Infectious Diseases (NIAID; R01-AI-51181) to
KAS as an investigator-initiated clinical trial, and by the Weill
Medical College General Clinical Research Center (M01-RR00047).
The Chiron Corporation supplied Proleukin; Sanofi Pasteur supplied
ALVAC vCP1452 and placebo, and BD Biosciences supplied reagents
and expertise for flow cytometry. Study corporate sponsors con-
tributed to the study design, analysis and interpretation of data, and
the decision to submit it for publication. No financial support was
received by the study investigators from the corporate sponsors. As
principal investigator, KAS had full access to all of the data in this
study and takes complete responsibility for the integrity of the data
and the accuracy of the data analysis.
REFERENCES
1. Jubault V, Burgard M, Le Corfec E, Costagliola D, Rouziox C, et al. (1998)
High rebound of plasma and cellular HIV load after discontinuation of
triple combination therapy. AIDS 12: 2358–2359.
2. Staszewski S, Miller V, Sabin C, Berger A, Hill AM, et al. (1998) Rebound of
HIV-1 viral load after suppression to very low levels. AIDS 12: 2360.
3. Davey RTJ, Bhat N, Yoder C, Chun T-W, Metcalf JA, et al. (1999) HIV-1 and
T cell dynamics after interruption of highly active antiretroviral therapy
(HAART) in patients with a history of sustained viral suppression. Proc Natl
Acad Sci USA 96: 15109–15114.
4. Smith K (2001) To cure chronic HIV infection, a new strategy is needed.
Curr Opin Immunol 13: 617–624.
5. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, et al. (1997)
Vigorous HIV-1-speciﬁc CD4
þ T cell responses associated with control of
viremia. Science 278: 1447–1450.
6. Rosenberg E, Altfeld M, Poon S, Phillips M, Wilkes B, et al. (2000) Immune
control of HIV-1 after early treatment of acute infection. Nature 407: 523–
526.
7. Kaufmann D, Lichterfeld MG, Altfeld M, Addo MM, Johnston MN, et al.
(2004) Limited durability of viral control following HIV infection. PLoS
Med 1: e36. doi:10.1371/journal.pmed.0010036
8. Cao Y, Qin L, Zhang L, Safrit J, Ho D (1995) Virologic and immunologic
characterization of long-term survivors of human immunodeﬁciency virus
type 1 infection. N Eng J Med 332: 201–208.
9. Bailey JR, Williams TM, Siliciano RF, Blankson JN (2006) Maintenance of
viral suppression in HIV-1-infected HLA-B*57
þ elite suppressors despite
CTL escape mutations. J Exp Med 203: 1357–1369.
10. Shankar P, Russo M, Harnisch B, Patterson M, Skolnik P, et al. (2000)
Impaired function of circulating HIV-speciﬁc CD8
þ T cells in chronic
human immunodeﬁciency virus infection. Blood 96: 3094–3101.
11. Lyasere C, Tilton JC, Johnson AJ, Younes S, Yassine-Diab B, et al. (2003)
Diminished proliferation of human immunodeﬁciency virus-speciﬁc CD4
þ
T cells is associated with diminished interleukin-2 (IL-2) production and is
recovered by exogenous IL-2. J Virol 77: 10900–10909.
12. Younes S-A, Yassine-Diab B, Dumont AR, Boulassel M-R, Grossman Z, et al.
(2003) HIV-1 viremia prevents the establishment of interleukin 2-
producing HIV-speciﬁc memory CD4
þ T cells endowed with proliferative
capacity. J Exp Med 198: 1909–1922.
13. Harari A, Vallelian F, Meylan PR, Pantaleo G (2005) Functional hetero-
geneity of memory CD4 T cell responses in different conditions of antigen
exposure and persistence. J Immunol 174: 1037–1045.
14. Smith KA (1988) Interleukin-2: Inception, impact, and implications.
Science 240: 1169–1176.
15. Murray H, Rubin B, Masur H, Roberts R (1984) Impaired production of
lymphokines and immune (gamma) interferon in the acquired immunode-
ﬁciency syndrome. N Eng J Med 310: 883–889.
16. Laurence J, Friedman S, Chartash E, Crow M, Posnett D (1989) Human
immunodeﬁciency virus infection of helper T cell clones: Early prolifer-
ative defects despite intact antigen-speciﬁc recognition and interleukin-4
secretion. J Clin Invest 83: 1843–1848.
17. Smith K, Jacobson E, Sohn T, Warren D, Emert R, et al. (2000) In vivo
assessment of antiviral reactivity in chronic HIV infection. HIV Clin Trials
1: 16–22.
18. Cantrell DA, Smith KA (1984) The interleukin-2 T-cell system: A new cell
growth model. Science 224: 1312–1316.
19. Meuer SC, Hussey RE, Cantrell DA, Hodgen JC, Schlossman SF, et al. (1984)
Triggering the T3-Ti antigen-receptor complex results in clonal T cell
proliferation through an interleukin 2-dependent autocrine pathway. Proc
Natl Acad Sci U S A 81: 1509–1513.
20. Ferrari G, Berend C, Ottinger J, Dodge R, Bartlett J, et al. (1997)
Replication-defective canarypox (ALVAC) vectors effectively activate
anti-human immunodeﬁciency virus-1 cytotoxic T lymphocytes present
in infected patients: Implications for antigen-speciﬁc immunotherapy.
Blood 90: 2406–2416.
21. Ferrari G, Humphrey W, McElrath M, Excler J, Duliege A, et al. (1997) Clade
B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reac-
tivities in uninfected volunteers. Proc Natl Acad Sci U S A 94: 1396–1401.
22. Clements-Mann M, Weinhold K, Matthews T, Graham B, Gorse G, et al.
(1998) Immune responses to human immunodeﬁciency virus (HIV) type 1
induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant
gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine
Evaluation Group. J Infect Dis 177: 1230–1246.
23. Evans T, Keefer M, Weinhold K, Wolff M, Monteﬁori D, et al. (1999) A
canarypox vaccine expressing multiple human immunodeﬁciency virus
type 1 genes given alone or with rgp120 elicits broad and durable CD8
þ
cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis
180: 290–298.
24. Smith KA (1990) Interleukin 2: The ﬁrst hormone of the immune system.
Scientiﬁc American 262: 50–57.
25. Kaplan G, Cohn Z, Smith K (1992) Rational immunotherapy with
interleukin-2. Bio/Technology 10: 157–162.
26. Garrity PA, Chen D, Rothenberg EV, Wold BJ (1994) Interleukin 2
transcription is regulated in vivo at the level of coordinated binding of
both constitutive and regulated factors. Mol Cell Bio 14: 2159–2169.
27. Rothenberg EV, Ward SB (1996) A dynamic assembly of diverse tran-
scription factors integrates activation and cell-type information for
interleukin 2 gene regulation. Proc Natl Acad Sci U S A 93: 9358–9365.
28. Levy Y, Gahery-Segard H, Durier C, Lascaux A-S, Goujard C, et al. (2005)
Immunological and virological efﬁcacy of a therapeutic immunization
combined with interleukin-2 in chronically infected patients. AIDS 19:
279–286.
29. Kilby J, Wang R, Mildvan D, Fischl M, Santana-Bagur J, et al. (2005) A phase
II randomized, partially blinded trial of antiretroviral therapy, HIV-speciﬁc
immunizations, and IL2 cycles to promote efﬁcient control of viral
replication (ACTG 5024). Abstract #525.12th Conference on Retroviruses
and Opportunistic Infections; 2005 22–25 February; Boston. Available:
http://www.retroconference.org/2005/cd/Abstracts/25066.htm.
30. Smith K (2003) The HIV vaccine saga. Med Immunol 2: 1.
31. Malkevitch N, Robert-Guroff M (2004) A call for replicating vector prime-
protein boost strategies in HIV vaccine design. Expert Rev Vaccines 3:
S105–117.
32. Smith K (2005) The continuing HIV vaccine saga: Naked emperors
alongside fairy godmothers. Med Immunol 4: 6.
33. Malkevitch NV, Patterson LJ, Aldrich MK, Wu Y, Venzon D, et al. (2006)
Durable protection of rhesus macaques immunized with a replicating
adenovirus-SIV multigene prime/protein boost vaccine regimen against a
second SIVmac251 rectal challenge: Role of SIV-speciﬁc CD8
þ Tc e l l
responses. Virology 353: 83–98.
www.plosclinicaltrials.org January | 2007 | e5 0013
Immunotherapy for HIV Infection